NewAmsterdam Pharma Co N.V. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2022 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
NewAmsterdam Pharma Co N.V. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2022 to Q4 2023.
  • NewAmsterdam Pharma Co N.V. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $130M, a 59.6% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $130M +$48.5M +59.6% Dec 31, 2023 10-K 2024-02-28
Q4 2022 $81.4M Dec 31, 2022 10-K 2024-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.